drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00390 | DB00910 | 1,252 | 1,041 | [
"DDInter554",
"DDInter1394"
] | Digoxin | Paricalcitol | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | Moderate | 1 | [
[
[
1252,
24,
1041
]
],
[
[
1252,
63,
386
],
[
386,
25,
1041
]
],
[
[
1252,
24,
1098
],
[
1098,
64,
1041
]
],
[
[
1252,
6,
8374
],
[
8374,... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paricalcitol"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholecalciferol"
],
[
... | Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Cholecalciferol and Cholecalciferol may lead to a major life threatening interaction when taken with Paricalcitol
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Dihydrotachysterol and Dihydro... |
DB00794 | DB12001 | 759 | 564 | [
"DDInter1521",
"DDInter7"
] | Primidone | Abemaciclib | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Major | 2 | [
[
[
759,
25,
564
]
],
[
[
759,
25,
868
],
[
868,
24,
564
]
],
[
[
759,
63,
58
],
[
58,
24,
564
]
],
[
[
759,
24,
392
],
[
392,
24,
... | [
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} ... | Primidone may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a... |
DB00572 | DB01591 | 85 | 667 | [
"DDInter136",
"DDInter1696"
] | Atropine | Solifenacin | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
85,
24,
667
]
],
[
[
85,
6,
7420
],
[
7420,
45,
667
]
],
[
[
85,
54,
19228
],
[
19228,
15,
667
]
],
[
[
85,
21,
28743
],
[
28743,
... | [
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Atropine",
"{u} (Compound) binds {v} (Gene)",
"CHRM4"
],
[
"CHRM4",
"{u} (Gene) is bound by {v} (Compound)",
... | Atropine (Compound) binds CHRM4 (Gene) and CHRM4 (Gene) is bound by Solifenacin (Compound)
Atropine (Compound) is included by Cholinergic Muscarinic Antagonists (Pharmacologic Class) and Cholinergic Muscarinic Antagonists (Pharmacologic Class) includes Solifenacin (Compound)
Atropine (Compound) causes Atrial fibrillati... |
DB00844 | DB01105 | 314 | 222 | [
"DDInter1257",
"DDInter1665"
] | Nalbuphine | Sibutramine | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
314,
24,
222
]
],
[
[
314,
21,
28741
],
[
28741,
60,
222
]
],
[
[
314,
63,
752
],
[
752,
23,
222
]
],
[
[
314,
63,
128
],
[
128,
... | [
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Nalbuphine",
"{u} (Compound) causes {v} (Side Effect)",
"Agitation"
],
[
"Agitation",
"{u} (Side Effect) is cau... | Nalbuphine (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Sibutramine (Compound)
Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Sibutram... |
DB00418 | DB05239 | 536 | 866 | [
"DDInter1650",
"DDInter425"
] | Secobarbital | Cobimetinib | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Moderate | 1 | [
[
[
536,
24,
866
]
],
[
[
536,
24,
214
],
[
214,
63,
866
]
],
[
[
536,
24,
888
],
[
888,
24,
866
]
],
[
[
536,
40,
1023
],
[
1023,
2... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen an... |
DB00283 | DB14575 | 701 | 733 | [
"DDInter395",
"DDInter674"
] | Clemastine | Eslicarbazepine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
701,
24,
733
]
],
[
[
701,
24,
1264
],
[
1264,
24,
733
]
],
[
[
701,
35,
1594
],
[
1594,
24,
733
]
],
[
[
701,
24,
1264
],
[
1264,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Clemastine (Compound) resembles Doxylamine (Compound) and Clemastine may cause a moderate interaction that could ... |
DB00446 | DB01265 | 597 | 1,477 | [
"DDInter351",
"DDInter1757"
] | Chloramphenicol | Telbivudine | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects. | Moderate | 1 | [
[
[
597,
24,
1477
]
],
[
[
597,
63,
1083
],
[
1083,
1,
1477
]
],
[
[
597,
24,
139
],
[
139,
1,
1477
]
],
[
[
597,
21,
28745
],
[
28745,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluridine"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine and Trifluridine (Compound) resembles Telbivudine (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) resembles Telbivu... |
DB00834 | DB00911 | 932 | 458 | [
"DDInter1215",
"DDInter1811"
] | Mifepristone | Tinidazole | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Moderate | 1 | [
[
[
932,
24,
458
]
],
[
[
932,
23,
112
],
[
112,
1,
458
]
],
[
[
932,
6,
8374
],
[
8374,
45,
458
]
],
[
[
932,
21,
28882
],
[
28882,
... | [
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinidazole"
]
],
[
[
"Mifepristone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Mifepristone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole (Compound) resembles Tinidazole (Compound)
Mifepristone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tinidazole (Compound)
Mifepristone (Compound) causes Body temperature increased ... |
DB00279 | DB09381 | 1,152 | 192 | [
"DDInter1074",
"DDInter678"
] | Liothyronine | Esterified estrogens | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of me... | Moderate | 1 | [
[
[
1152,
24,
192
]
],
[
[
1152,
24,
1264
],
[
1264,
23,
192
]
],
[
[
1152,
24,
5
],
[
5,
24,
192
]
],
[
[
1152,
63,
1685
],
[
1685,
... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
... | Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Esterified estrogens
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and... |
DB00069 | DB08860 | 367 | 788 | [
"DDInter946",
"DDInter1479"
] | Interferon alfacon-1 | Pitavastatin | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More sp... | Moderate | 1 | [
[
[
367,
24,
788
]
],
[
[
367,
24,
671
],
[
671,
1,
788
]
],
[
[
367,
24,
700
],
[
700,
40,
788
]
],
[
[
367,
24,
126
],
[
126,
23,
... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluva... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin (Compound) resembles Pitavastatin (Compound)
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin (Compound) rese... |
DB00704 | DB05015 | 267 | 1,077 | [
"DDInter1263",
"DDInter174"
] | Naltrexone | Belinostat | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Moderate | 1 | [
[
[
267,
24,
1077
]
],
[
[
267,
63,
482
],
[
482,
24,
1077
]
],
[
[
267,
24,
637
],
[
637,
63,
1077
]
],
[
[
267,
24,
478
],
[
478,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belinostat"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia ... |
DB00075 | DB05679 | 541 | 1,683 | [
"DDInter1250",
"DDInter1907"
] | Muromonab | Ustekinumab | Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
541,
24,
1683
]
],
[
[
541,
23,
1461
],
[
1461,
23,
1683
]
],
[
[
541,
23,
1193
],
[
1193,
62,
1683
]
],
[
[
541,
24,
1129
],
[
1129,
... | [
[
[
"Muromonab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Muromonab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
... | Muromonab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Muromonab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc glucon... |
DB00726 | DB12500 | 1,164 | 283 | [
"DDInter1876",
"DDInter714"
] | Trimipramine | Fedratinib | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1164,
24,
283
]
],
[
[
1164,
25,
351
],
[
351,
23,
283
]
],
[
[
1164,
63,
1419
],
[
1419,
24,
283
]
],
[
[
1164,
35,
401
],
[
401,
... | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Trimipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Riboci... | Trimipramine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a ... |
DB00601 | DB08880 | 453 | 1,510 | [
"DDInter1073",
"DDInter1771"
] | Linezolid | Teriflunomide | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
453,
25,
1510
]
],
[
[
453,
24,
1144
],
[
1144,
24,
1510
]
],
[
[
453,
63,
10
],
[
10,
24,
1510
]
],
[
[
453,
24,
148
],
[
148,
... | [
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglin... | Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapson... |
DB00321 | DB00719 | 21 | 1,219 | [
"DDInter78",
"DDInter149"
] | Amitriptyline | Azatadine | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Moderate | 1 | [
[
[
21,
35,
1219
]
],
[
[
21,
35,
13
],
[
13,
24,
1219
]
],
[
[
21,
35,
830
],
[
830,
1,
1219
]
],
[
[
21,
1,
114
],
[
114,
1,
... | [
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate intera... | Amitriptyline (Compound) resembles Azatadine (Compound) and
Amitriptyline (Compound) resembles Cyproheptadine (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases whe... |
DB00982 | DB01234 | 1,517 | 1,220 | [
"DDInter991",
"DDInter513"
] | Isotretinoin | Dexamethasone | Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
1517,
24,
1220
]
],
[
[
1517,
63,
175
],
[
175,
40,
1220
]
],
[
[
1517,
63,
167
],
[
167,
1,
1220
]
],
[
[
1517,
24,
617
],
[
617,
... | [
[
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]... | Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamethasone (Compound)
Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles D... |
DB11095 | DB11793 | 235 | 738 | [
"DDInter505",
"DDInter1297"
] | Desirudin | Niraparib | Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three dis... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
235,
24,
738
]
],
[
[
235,
64,
1213
],
[
1213,
24,
738
]
],
[
[
235,
63,
578
],
[
578,
24,
738
]
],
[
[
235,
25,
405
],
[
405,
2... | [
[
[
"Desirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Desirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
... | Desirudin may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a mod... |
DB00835 | DB09118 | 100 | 1,580 | [
"DDInter245",
"DDInter1711"
] | Brompheniramine | Stiripentol | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
100,
24,
1580
]
],
[
[
100,
24,
1532
],
[
1532,
24,
1580
]
],
[
[
100,
24,
1609
],
[
1609,
63,
1580
]
],
[
[
100,
63,
1219
],
[
1219,
... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
... | Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyver... |
DB01097 | DB01406 | 1,377 | 984 | [
"DDInter1033",
"DDInter472"
] | Leflunomide | Danazol | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Major | 2 | [
[
[
1377,
25,
984
]
],
[
[
1377,
25,
1546
],
[
1546,
1,
984
]
],
[
[
1377,
64,
1573
],
[
1573,
1,
984
]
],
[
[
1377,
64,
1026
],
[
1026,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danazol"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methyltestosterone"
],
[
"Methyltestosterone... | Leflunomide may lead to a major life threatening interaction when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Danazol (Compound)
Leflunomide may lead to a major life threatening interaction when taken with Prednisone and Prednisone (Compound) resembles Danazol (Compound)
Leflunomide may le... |
DB00317 | DB13179 | 883 | 68 | [
"DDInter810",
"DDInter1882"
] | Gefitinib | Troleandomycin | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | A macrolide antibiotic that is similar to erythromycin. | Moderate | 1 | [
[
[
883,
24,
68
]
],
[
[
883,
63,
1101
],
[
1101,
23,
68
]
],
[
[
883,
24,
267
],
[
267,
24,
68
]
],
[
[
883,
40,
1195
],
[
1195,
24... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltre... |
DB01320 | DB06603 | 651 | 39 | [
"DDInter783",
"DDInter1387"
] | Fosphenytoin | Panobinostat | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
651,
25,
39
]
],
[
[
651,
63,
112
],
[
112,
23,
39
]
],
[
[
651,
63,
912
],
[
912,
24,
39
]
],
[
[
651,
24,
1683
],
[
1683,
24,
... | [
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"M... | Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Interferon ... |
DB00023 | DB00263 | 305 | 1,029 | [
"DDInter127",
"DDInter1727"
] | Asparaginase Escherichia coli | Sulfisoxazole | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms. | Moderate | 1 | [
[
[
305,
24,
1029
]
],
[
[
305,
24,
1247
],
[
1247,
40,
1029
]
],
[
[
305,
24,
161
],
[
161,
1,
1029
]
],
[
[
305,
24,
245
],
[
245,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfisoxazole"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) resembles Sulfisoxazole (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and... |
DB11703 | DB15035 | 405 | 503 | [
"DDInter9",
"DDInter1959"
] | Acalabrutinib | Zanubrutinib | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Major | 2 | [
[
[
405,
25,
503
]
],
[
[
405,
63,
1094
],
[
1094,
24,
503
]
],
[
[
405,
24,
982
],
[
982,
24,
503
]
],
[
[
405,
64,
39
],
[
39,
25,... | [
[
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
],
[
"M... | Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib ... |
DB00346 | DB06691 | 472 | 849 | [
"DDInter44",
"DDInter1155"
] | Alfuzosin | Mepyramine | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
472,
24,
849
]
],
[
[
472,
7,
2216
],
[
2216,
46,
849
]
],
[
[
472,
24,
770
],
[
770,
24,
849
]
],
[
[
472,
24,
407
],
[
407,
63... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Alfuzosin",
"{u} (Compound) upregulates {v} (Gene)",
"PAK1"
],
[
"PAK1",
"{u} (Gene) is upregulated by {v} (Compo... | Alfuzosin (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Mepyramine (Compound)
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Alfuzosin ... |
DB01182 | DB09104 | 371 | 286 | [
"DDInter1534",
"DDInter1118"
] | Propafenone | Magnesium hydroxide | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
371,
24,
286
]
],
[
[
371,
24,
820
],
[
820,
23,
286
]
],
[
[
371,
63,
401
],
[
401,
23,
286
]
],
[
[
371,
1,
772
],
[
772,
23,
... | [
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
... | Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Promethazi... |
DB00741 | DB11095 | 167 | 235 | [
"DDInter885",
"DDInter505"
] | Hydrocortisone | Desirudin | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three dis... | Major | 2 | [
[
[
167,
25,
235
]
],
[
[
167,
24,
1004
],
[
1004,
24,
235
]
],
[
[
167,
62,
1461
],
[
1461,
24,
235
]
],
[
[
167,
63,
529
],
[
529,
... | [
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
],
[
... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Vi... |
DB00741 | DB12887 | 167 | 1,598 | [
"DDInter885",
"DDInter1750"
] | Hydrocortisone | Tazemetostat | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
167,
24,
1598
]
],
[
[
167,
63,
1324
],
[
1324,
24,
1598
]
],
[
[
167,
1,
891
],
[
891,
24,
1598
]
],
[
[
167,
40,
870
],
[
870,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Hydrocortisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate inte... |
DB06410 | DB06723 | 1,196 | 115 | [
"DDInter595",
"DDInter58"
] | Doxercalciferol | Aluminum hydroxide | Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney d... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Major | 2 | [
[
[
1196,
25,
115
]
],
[
[
1196,
63,
1482
],
[
1482,
23,
115
]
],
[
[
1196,
63,
463
],
[
463,
24,
115
]
],
[
[
1196,
64,
160
],
[
160,
... | [
[
[
"Doxercalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Doxercalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
],
[
... | Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Rifampi... |
DB01764 | DB09330 | 805 | 985 | [
"DDInter469",
"DDInter1352"
] | Dalfopristin | Osimertinib | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
805,
24,
985
]
],
[
[
805,
63,
608
],
[
608,
23,
985
]
],
[
[
805,
25,
1478
],
[
1478,
24,
985
]
],
[
[
805,
63,
134
],
[
134,
2... | [
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
... | Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Dalfopristin may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a... |
DB06176 | DB11581 | 1,342 | 1,456 | [
"DDInter1616",
"DDInter1926"
] | Romidepsin | Venetoclax | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Moderate | 1 | [
[
[
1342,
24,
1456
]
],
[
[
1342,
24,
259
],
[
259,
24,
1456
]
],
[
[
1342,
24,
241
],
[
241,
63,
1456
]
],
[
[
1342,
63,
248
],
[
248,
... | [
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
... | Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib and Erdaf... |
DB01018 | DB09112 | 1,364 | 1,455 | [
"DDInter847",
"DDInter1306"
] | Guanfacine | Nitrous acid | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
1364,
24,
1455
]
],
[
[
1364,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
1364,
63,
1214
],
[
1214,
24,
1455
]
],
[
[
1364,
40,
390
],
[
390... | [
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
... | Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and... |
DB00745 | DB11691 | 307 | 1,499 | [
"DDInter1236",
"DDInter1258"
] | Modafinil | Naldemedine | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Minor | 0 | [
[
[
307,
23,
1499
]
],
[
[
307,
62,
723
],
[
723,
24,
1499
]
],
[
[
307,
24,
1670
],
[
1670,
24,
1499
]
],
[
[
307,
25,
1406
],
[
1406,
... | [
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naldemedine"
]
],
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aprepitant"
],
[
"... | Modafinil may cause a minor interaction that can limit clinical effects when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglusta... |
DB01181 | DB06674 | 1,532 | 908 | [
"DDInter906",
"DDInter837"
] | Ifosfamide | Golimumab | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
1532,
25,
908
]
],
[
[
1532,
63,
1461
],
[
1461,
23,
908
]
],
[
[
1532,
63,
828
],
[
828,
24,
908
]
],
[
[
1532,
24,
200
],
[
200,
... | [
[
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Golimumab
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone ma... |
DB00188 | DB00812 | 168 | 998 | [
"DDInter222",
"DDInter1451"
] | Bortezomib | Phenylbutazone | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Minor | 0 | [
[
[
168,
23,
998
]
],
[
[
168,
23,
804
],
[
804,
40,
998
]
],
[
[
168,
23,
307
],
[
307,
1,
998
]
],
[
[
168,
25,
362
],
[
362,
1,
... | [
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenylbutazone"
]
],
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfinpyrazone"
],
... | Bortezomib may cause a minor interaction that can limit clinical effects when taken with Sulfinpyrazone and Sulfinpyrazone (Compound) resembles Phenylbutazone (Compound)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Phenylbutazone (... |
DB00562 | DB11110 | 1,014 | 603 | [
"DDInter188",
"DDInter1115"
] | Benzthiazide | Magnesium citrate | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
1014,
24,
603
]
],
[
[
1014,
25,
57
],
[
57,
24,
603
]
],
[
[
1014,
24,
870
],
[
870,
24,
603
]
],
[
[
1014,
40,
674
],
[
674,
2... | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Benzthiazide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Benzthiazide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortiso... |
DB00544 | DB01324 | 970 | 178 | [
"DDInter757",
"DDInter1490"
] | Fluorouracil | Polythiazide | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
970,
24,
178
]
],
[
[
970,
24,
674
],
[
674,
40,
178
]
],
[
[
970,
63,
323
],
[
323,
40,
178
]
],
[
[
970,
21,
28852
],
[
28852,
... | [
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
... | Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide (Co... |
DB00818 | DB01177 | 898 | 77 | [
"DDInter1538",
"DDInter904"
] | Propofol | Idarubicin | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
898,
24,
77
]
],
[
[
898,
6,
6017
],
[
6017,
45,
77
]
],
[
[
898,
21,
28931
],
[
28931,
60,
77
]
],
[
[
898,
23,
112
],
[
112,
2... | [
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Propofol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Propofol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Idarubicin (Compound)
Propofol (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Idarubicin (Compound)
Propofol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metro... |
DB00014 | DB01278 | 521 | 1,021 | [
"DDInter839",
"DDInter1506"
] | Goserelin | Pramlintide | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
521,
24,
1021
]
],
[
[
521,
25,
839
],
[
839,
24,
1021
]
],
[
[
521,
24,
1539
],
[
1539,
24,
1021
]
],
[
[
521,
24,
9
],
[
9,
63... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grepafloxacin"
],
[
"Grepaflo... | Goserelin may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin may cau... |
DB00813 | DB01183 | 704 | 173 | [
"DDInter722",
"DDInter1262"
] | Fentanyl | Naloxone | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Naloxone is an opioid antagonist medication used to block or reverse the effects of opioid drugs, particularly within the setting of drug overdoses which are rapidly becoming a leading cause of death worldwide. More specifically, naloxone has a high affinity for μ-opioid receptors, where it acts as an inverse agonist, ... | Moderate | 1 | [
[
[
704,
24,
173
]
],
[
[
704,
64,
475
],
[
475,
24,
173
]
],
[
[
704,
64,
267
],
[
267,
40,
173
]
],
[
[
704,
6,
7940
],
[
7940,
45... | [
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
],
[
[
"Fentanyl",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"... | Fentanyl may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Naloxone
Fentanyl may lead to a major life threatening interaction when taken with Naltrexone and Naltrexone (Compound) resembles Naloxone (Comp... |
DB01098 | DB05773 | 14 | 1,047 | [
"DDInter1622",
"DDInter1848"
] | Rosuvastatin | Trastuzumab emtansine | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
14,
24,
1047
]
],
[
[
14,
64,
1091
],
[
1091,
24,
1047
]
],
[
[
14,
24,
375
],
[
375,
63,
1047
]
],
[
[
14,
63,
1112
],
[
1112,
... | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Rosuvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
... | Rosuvastatin may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol an... |
DB00030 | DB01165 | 1,685 | 1,539 | [
"DDInter934",
"DDInter1325"
] | Insulin human | Ofloxacin | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Major | 2 | [
[
[
1685,
25,
1539
]
],
[
[
1685,
25,
1176
],
[
1176,
1,
1539
]
],
[
[
1685,
25,
956
],
[
956,
40,
1539
]
],
[
[
1685,
24,
1021
],
[
1021,... | [
[
[
"Insulin human",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ofloxacin"
]
],
[
[
"Insulin human",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
... | Insulin human may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Ofloxacin (Compound)
Insulin human may lead to a major life threatening interaction when taken with Norfloxacin and Norfloxacin (Compound) resembles Ofloxacin (Compound)
Insulin human may ca... |
DB00397 | DB06704 | 1,466 | 247 | [
"DDInter1458",
"DDInter951"
] | Phenylpropanolamine | Iobenguane (I-123) | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Moderate | 1 | [
[
[
1466,
37,
247
]
],
[
[
1466,
6,
7390
],
[
7390,
45,
247
]
],
[
[
1466,
18,
9226
],
[
9226,
57,
247
]
],
[
[
1466,
21,
28787
],
[
28787... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Phenylpropanolamine",
"{u} (Compound) binds {v} (Gen... | Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Phenylpropanolamine may lead to a major life threatening interaction when taken with Iobenguane
Phenylpropanolamine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound)
Phenyl... |
DB00635 | DB11652 | 1,573 | 1,155 | [
"DDInter1515",
"DDInter1891"
] | Prednisone | Tucatinib | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
1573,
24,
1155
]
],
[
[
1573,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
1573,
23,
659
],
[
659,
24,
1155
]
],
[
[
1573,
24,
609
],
[
609,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Prednisone may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol ... |
DB01234 | DB09035 | 1,220 | 410 | [
"DDInter513",
"DDInter1308"
] | Dexamethasone | Nivolumab | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability. It was developed by Bristol Myers Squibb. N... | Moderate | 1 | [
[
[
1220,
24,
410
]
],
[
[
1220,
40,
1573
],
[
1573,
24,
410
]
],
[
[
1220,
1,
175
],
[
175,
24,
410
]
],
[
[
1220,
25,
1019
],
[
1019,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nivolumab"
]
],
[
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a mo... | Dexamethasone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Nivolumab
Dexamethasone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB01114 | DB09488 | 272 | 103 | [
"DDInter362",
"DDInter23"
] | Chlorpheniramine | Acrivastine | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
272,
24,
103
]
],
[
[
272,
23,
771
],
[
771,
62,
103
]
],
[
[
272,
63,
1405
],
[
1405,
24,
103
]
],
[
[
272,
24,
1264
],
[
1264,
... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
... | Chlorpheniramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Acrivastine
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cyclob... |
DB01242 | DB05812 | 1,237 | 1,374 | [
"DDInter410",
"DDInter8"
] | Clomipramine | Abiraterone | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
1237,
24,
1374
]
],
[
[
1237,
6,
1829
],
[
1829,
45,
1374
]
],
[
[
1237,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
1237,
62,
112
],
[
11... | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Clomipramine",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
... | Clomipramine (Compound) binds ALB (Gene) and ALB (Gene) is bound by Abiraterone (Compound)
Clomipramine (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Clomipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole... |
DB01268 | DB13074 | 1,151 | 877 | [
"DDInter1731",
"DDInter1110"
] | Sunitinib | Macimorelin | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
1151,
25,
877
]
],
[
[
1151,
62,
112
],
[
112,
23,
877
]
],
[
[
1151,
24,
1320
],
[
1320,
24,
877
]
],
[
[
1151,
25,
651
],
[
651,
... | [
[
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Sunitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Sunitinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagoli... |
DB00163 | DB06674 | 1,461 | 908 | [
"DDInter1943",
"DDInter837"
] | Vitamin E | Golimumab | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Minor | 0 | [
[
[
1461,
23,
908
]
],
[
[
1461,
62,
66
],
[
66,
24,
908
]
],
[
[
1461,
24,
1409
],
[
1409,
24,
908
]
],
[
[
1461,
24,
450
],
[
450,
... | [
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Golimumab"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Efalizumab"
],
[
"Ef... | Vitamin E may cause a minor interaction that can limit clinical effects when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may ... |
DB00414 | DB00574 | 590 | 121 | [
"DDInter16",
"DDInter717"
] | Acetohexamide | Fenfluramine | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Moderate | 1 | [
[
[
590,
24,
121
]
],
[
[
590,
24,
1144
],
[
1144,
63,
121
]
],
[
[
590,
24,
24
],
[
24,
24,
121
]
],
[
[
590,
63,
831
],
[
831,
24,... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin an... |
DB00427 | DB00543 | 1,233 | 87 | [
"DDInter1879",
"DDInter82"
] | Triprolidine | Amoxapine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Moderate | 1 | [
[
[
1233,
24,
87
]
],
[
[
1233,
24,
1119
],
[
1119,
1,
87
]
],
[
[
1233,
63,
905
],
[
905,
40,
87
]
],
[
[
1233,
63,
1174
],
[
1174,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlordiazepoxide"
],... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Chlordiazepoxide and Chlordiazepoxide (Compound) resembles Amoxapine (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Amoxapine... |
DB01261 | DB01365 | 170 | 280 | [
"DDInter1679",
"DDInter1151"
] | Sitagliptin | Mephentermine | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type depen... | Moderate | 1 | [
[
[
170,
24,
280
]
],
[
[
170,
63,
1445
],
[
1445,
1,
280
]
],
[
[
170,
24,
1529
],
[
1529,
1,
280
]
],
[
[
170,
24,
22
],
[
22,
40,... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephentermine"
]
],
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
]... | Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Mephentermine (Compound)
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles M... |
DB00761 | DB01403 | 1,621 | 9 | [
"DDInter1497",
"DDInter1175"
] | Potassium chloride | Methotrimeprazine | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Major | 2 | [
[
[
1621,
25,
9
]
],
[
[
1621,
25,
1178
],
[
1178,
40,
9
]
],
[
[
1621,
64,
1164
],
[
1164,
1,
9
]
],
[
[
1621,
64,
684
],
[
684,
40... | [
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluoperazine"
],
[
... | Potassium chloride may lead to a major life threatening interaction when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Potassium chloride may lead to a major life threatening interaction when taken with Trimipramine and Trimipramine (Compound) resembles Methotrimeprazi... |
DB00204 | DB01362 | 228 | 497 | [
"DDInter580",
"DDInter960"
] | Dofetilide | Iohexol | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Moderate | 1 | [
[
[
228,
24,
497
]
],
[
[
228,
24,
258
],
[
258,
40,
497
]
],
[
[
228,
21,
28787
],
[
28787,
60,
497
]
],
[
[
228,
23,
891
],
[
891,
... | [
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
],
[
... | Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol and Iodixanol (Compound) resembles Iohexol (Compound)
Dofetilide (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iohexol (Compound)
Dofetilide may cause a minor interaction that can ... |
DB09073 | DB12825 | 951 | 1,375 | [
"DDInter1379",
"DDInter1032"
] | Palbociclib | Lefamulin | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
951,
24,
1375
]
],
[
[
951,
24,
159
],
[
159,
63,
1375
]
],
[
[
951,
63,
966
],
[
966,
24,
1375
]
],
[
[
951,
64,
976
],
[
976,
... | [
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
... | Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and... |
DB06699 | DB08875 | 774 | 1,618 | [
"DDInter493",
"DDInter262"
] | Degarelix | Cabozantinib | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
774,
25,
1618
]
],
[
[
774,
62,
112
],
[
112,
23,
1618
]
],
[
[
774,
24,
1032
],
[
1032,
63,
1618
]
],
[
[
774,
63,
480
],
[
480,
... | [
[
[
"Degarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Degarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Degarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol and ... |
DB00008 | DB01362 | 491 | 497 | [
"DDInter1407",
"DDInter960"
] | Peginterferon alfa-2a | Iohexol | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
491,
25,
497
]
],
[
[
491,
24,
242
],
[
242,
63,
497
]
],
[
[
491,
24,
33
],
[
33,
24,
497
]
],
[
[
491,
24,
1267
],
[
1267,
64,... | [
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Am... |
DB00747 | DB04861 | 1,442 | 1,592 | [
"DDInter1647",
"DDInter1271"
] | Scopolamine | Nebivolol | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Moderate | 1 | [
[
[
1442,
24,
1592
]
],
[
[
1442,
21,
28762
],
[
28762,
60,
1592
]
],
[
[
1442,
24,
1528
],
[
1528,
24,
1592
]
],
[
[
1442,
63,
19
],
[
19... | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Scopolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is cause... | Scopolamine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nebivolol (Compound)
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine and Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Ne... |
DB00450 | DB08865 | 78 | 1,593 | [
"DDInter603",
"DDInter448"
] | Droperidol | Crizotinib | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
78,
25,
1593
]
],
[
[
78,
18,
4430
],
[
4430,
46,
1593
]
],
[
[
78,
21,
28921
],
[
28921,
60,
1593
]
],
[
[
78,
24,
286
],
[
286,
... | [
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Droperidol",
"{u} (Compound) downregulates {v} (Gene)",
"CHIC2"
],
[
"CHIC2",
"{u} (Gene) is upregulated by {v} (Compound)",
... | Droperidol (Compound) downregulates CHIC2 (Gene) and CHIC2 (Gene) is upregulated by Crizotinib (Compound)
Droperidol (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Crizotinib (Compound)
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Magnesi... |
DB08820 | DB08873 | 1,478 | 74 | [
"DDInter997",
"DDInter221"
] | Ivacaftor | Boceprevir | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | Major | 2 | [
[
[
1478,
25,
74
]
],
[
[
1478,
6,
4973
],
[
4973,
45,
74
]
],
[
[
1478,
54,
19146
],
[
19146,
15,
74
]
],
[
[
1478,
21,
28792
],
[
28792,... | [
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
],
[
[
"Ivacaftor",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Boceprevir"... | Ivacaftor (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Boceprevir (Compound)
Ivacaftor (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Boceprevir (Compound)
Ivacaftor (Compound) causes Gastrointestinal disorde... |
DB00738 | DB11827 | 485 | 433 | [
"DDInter1420",
"DDInter669"
] | Pentamidine | Ertugliflozin | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
485,
24,
433
]
],
[
[
485,
64,
695
],
[
695,
24,
433
]
],
[
[
485,
24,
959
],
[
959,
24,
433
]
],
[
[
485,
63,
521
],
[
521,
24,... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozap... | Pentamidine may lead to a major life threatening interaction when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause... |
DB06441 | DB10672 | 936 | 297 | [
"DDInter283",
"DDInter417"
] | Cangrelor | Clove | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Clove allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
936,
23,
297
]
],
[
[
936,
25,
235
],
[
235,
62,
297
]
],
[
[
936,
64,
1564
],
[
1564,
23,
297
]
],
[
[
936,
63,
1512
],
[
1512,
... | [
[
[
"Cangrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Cangrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{... | Cangrelor may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a minor interaction that can limit clinical effects when taken with Clove
Cangrelor may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may cause a minor interaction that... |
DB09312 | DB11601 | 967 | 1,270 | [
"DDInter106",
"DDInter1889"
] | Antithymocyte immunoglobulin (rabbit) | Tuberculin purified protein derivative | Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin i... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
967,
24,
1270
]
],
[
[
967,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
967,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
967,
63,
599
],
[
599,
... | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that ... | Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moder... |
DB01088 | DB09112 | 714 | 1,455 | [
"DDInter908",
"DDInter1306"
] | Iloprost | Nitrous acid | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
714,
24,
1455
]
],
[
[
714,
63,
312
],
[
312,
24,
1455
]
],
[
[
714,
24,
772
],
[
772,
24,
1455
]
],
[
[
714,
24,
433
],
[
433,
... | [
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eplerenone"
],
[
... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Eplerenone and Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and Carvedil... |
DB00358 | DB00734 | 1,010 | 1,664 | [
"DDInter1140",
"DDInter1605"
] | Mefloquine | Risperidone | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Moderate | 1 | [
[
[
1010,
24,
1664
]
],
[
[
1010,
25,
924
],
[
924,
40,
1664
]
],
[
[
1010,
24,
519
],
[
519,
40,
1664
]
],
[
[
1010,
6,
4973
],
[
4973,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
],
[
"Iloperid... | Mefloquine may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) resembles Risperidone (Compound)
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Risperidone (Compound)
Mefloqu... |
DB05679 | DB09036 | 1,683 | 812 | [
"DDInter1907",
"DDInter1668"
] | Ustekinumab | Siltuximab | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Moderate | 1 | [
[
[
1683,
24,
812
]
],
[
[
1683,
23,
1193
],
[
1193,
62,
812
]
],
[
[
1683,
62,
1461
],
[
1461,
23,
812
]
],
[
[
1683,
24,
287
],
[
287,
... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Ustekinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
... | Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Siltuximab
Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vit... |
DB00655 | DB14740 | 559 | 771 | [
"DDInter682",
"DDInter881"
] | Estrone | Hyaluronidase | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permea... | Minor | 0 | [
[
[
559,
23,
771
]
],
[
[
559,
40,
1438
],
[
1438,
23,
771
]
],
[
[
559,
24,
167
],
[
167,
23,
771
]
],
[
[
559,
1,
35
],
[
35,
23,
... | [
[
[
"Estrone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Estrone",
"{u} (Compound) resembles {v} (Compound)",
"Estradiol"
],
[
"Estradiol",
"{u} may cause a minor interact... | Estrone (Compound) resembles Estradiol (Compound) and Estradiol may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can lim... |
DB08895 | DB15093 | 976 | 1,654 | [
"DDInter1825",
"DDInter1698"
] | Tofacitinib | Somapacitan | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
976,
24,
1654
]
],
[
[
976,
63,
608
],
[
608,
23,
1654
]
],
[
[
976,
64,
168
],
[
168,
23,
1654
]
],
[
[
976,
63,
1215
],
[
1215,
... | [
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Tofacitinib may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a... |
DB01059 | DB06335 | 956 | 761 | [
"DDInter1313",
"DDInter1646"
] | Norfloxacin | Saxagliptin | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
956,
24,
761
]
],
[
[
956,
6,
7524
],
[
7524,
45,
761
]
],
[
[
956,
21,
28722
],
[
28722,
60,
761
]
],
[
[
956,
24,
1491
],
[
1491,
... | [
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Norfloxacin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound... | Norfloxacin (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Saxagliptin (Compound)
Norfloxacin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Saxagliptin (Compound)
Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Mido... |
DB08870 | DB08895 | 850 | 976 | [
"DDInter228",
"DDInter1825"
] | Brentuximab vedotin | Tofacitinib | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
850,
25,
976
]
],
[
[
850,
24,
214
],
[
214,
63,
976
]
],
[
[
850,
63,
998
],
[
998,
24,
976
]
],
[
[
850,
24,
868
],
[
868,
24,... | [
[
[
"Brentuximab vedotin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00372 | DB00899 | 999 | 411 | [
"DDInter1793",
"DDInter1579"
] | Thiethylperazine | Remifentanil | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depress... | Moderate | 1 | [
[
[
999,
24,
411
]
],
[
[
999,
24,
1322
],
[
1322,
40,
411
]
],
[
[
999,
24,
704
],
[
704,
1,
411
]
],
[
[
999,
24,
662
],
[
662,
24... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remifentanil"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil and Alfentanil (Compound) resembles Remifentanil (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Remifentanil... |
DB00436 | DB01278 | 323 | 1,021 | [
"DDInter179",
"DDInter1506"
] | Bendroflumethiazide | Pramlintide | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
323,
24,
1021
]
],
[
[
323,
24,
708
],
[
708,
63,
1021
]
],
[
[
323,
23,
1507
],
[
1507,
24,
1021
]
],
[
[
323,
24,
891
],
[
891,
... | [
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticot... | Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Bendroflumethiazide may cause a minor interaction that can limit clinical effects when taken wit... |
DB00685 | DB14520 | 1,299 | 1,229 | [
"DDInter1887",
"DDInter1785"
] | Trovafloxacin | Tetraferric tricitrate decahydrate | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014. | Moderate | 1 | [
[
[
1299,
24,
1229
]
],
[
[
1299,
24,
1096
],
[
1096,
23,
1229
]
],
[
[
1299,
1,
1467
],
[
1467,
24,
1229
]
],
[
[
1299,
24,
1096
],
[
109... | [
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Tetraferric tricitrate decahydrate
Trovafloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin may c... |
DB01211 | DB09330 | 609 | 985 | [
"DDInter393",
"DDInter1352"
] | Clarithromycin | Osimertinib | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
609,
25,
985
]
],
[
[
609,
63,
168
],
[
168,
23,
985
]
],
[
[
609,
62,
1247
],
[
1247,
23,
985
]
],
[
[
609,
25,
1478
],
[
1478,
... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"B... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole... |
DB00704 | DB11691 | 267 | 1,499 | [
"DDInter1263",
"DDInter1258"
] | Naltrexone | Naldemedine | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
267,
24,
1499
]
],
[
[
267,
35,
1159
],
[
1159,
24,
1499
]
],
[
[
267,
63,
1419
],
[
1419,
24,
1499
]
],
[
[
267,
24,
851
],
[
851,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Naltrexone",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken ... | Naltrexone (Compound) resembles Methylnaltrexone (Compound) and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Methylnaltrexone and Methyl
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate int... |
DB00690 | DB01105 | 1,216 | 222 | [
"DDInter762",
"DDInter1665"
] | Flurazepam | Sibutramine | A benzodiazepine derivative used mainly as a hypnotic. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
1216,
24,
222
]
],
[
[
1216,
6,
8374
],
[
8374,
45,
222
]
],
[
[
1216,
21,
29356
],
[
29356,
60,
222
]
],
[
[
1216,
24,
384
],
[
384,
... | [
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Flurazepam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Flurazepam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Flurazepam (Compound) causes Salivary hypersecretion (Side Effect) and Salivary hypersecretion (Side Effect) is caused by Sibutramine (Compound)
Flurazepam may cause a moderate interaction that could exacerbate diseases when ... |
DB01045 | DB06210 | 463 | 72 | [
"DDInter1590",
"DDInter631"
] | Rifampicin | Eltrombopag | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Moderate | 1 | [
[
[
463,
24,
72
]
],
[
[
463,
6,
3486
],
[
3486,
45,
72
]
],
[
[
463,
25,
384
],
[
384,
63,
72
]
],
[
[
463,
64,
467
],
[
467,
24,
... | [
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Rifampicin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)"... | Rifampicin (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Eltrombopag (Compound)
Rifampicin may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Rifampicin may lead to a major ... |
DB00446 | DB01100 | 597 | 1,568 | [
"DDInter351",
"DDInter1470"
] | Chloramphenicol | Pimozide | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Major | 2 | [
[
[
597,
25,
1568
]
],
[
[
597,
6,
7524
],
[
7524,
45,
1568
]
],
[
[
597,
18,
10780
],
[
10780,
57,
1568
]
],
[
[
597,
21,
28666
],
[
2866... | [
[
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pimozide"
]
],
[
[
"Chloramphenicol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
... | Chloramphenicol (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Pimozide (Compound)
Chloramphenicol (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is downregulated by Pimozide (Compound)
Chloramphenicol (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect... |
DB00539 | DB00976 | 11 | 1,056 | [
"DDInter1837",
"DDInter1758"
] | Toremifene | Telithromycin | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Major | 2 | [
[
[
11,
25,
1056
]
],
[
[
11,
64,
1570
],
[
1570,
40,
1056
]
],
[
[
11,
6,
7950
],
[
7950,
45,
1056
]
],
[
[
11,
21,
28817
],
[
28817,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telithromycin"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Azithromycin"
],
[
"Azithromycin",
... | Toremifene may lead to a major life threatening interaction when taken with Azithromycin and Azithromycin (Compound) resembles Telithromycin (Compound)
Toremifene (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Telithromycin (Compound)
Toremifene (Compound) causes Vision blurred (Side Effect) and Vision bl... |
DB00075 | DB00193 | 541 | 534 | [
"DDInter1250",
"DDInter1841"
] | Muromonab | Tramadol | Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type... | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Major | 2 | [
[
[
541,
25,
534
]
],
[
[
541,
25,
976
],
[
976,
63,
534
]
],
[
[
541,
24,
1662
],
[
1662,
63,
534
]
],
[
[
541,
25,
497
],
[
497,
6... | [
[
[
"Muromonab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
]
],
[
[
"Muromonab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may... | Muromonab may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Tramadol
Muromonab may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric aci... |
DB00782 | DB01114 | 1,123 | 272 | [
"DDInter1535",
"DDInter362"
] | Propantheline | Chlorpheniramine | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
1123,
24,
272
]
],
[
[
1123,
24,
358
],
[
358,
63,
272
]
],
[
[
1123,
63,
128
],
[
128,
24,
272
]
],
[
[
1123,
21,
28705
],
[
28705,
... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
... | Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Dexbr... |
DB00197 | DB00808 | 1,324 | 1,605 | [
"DDInter1881",
"DDInter916"
] | Troglitazone | Indapamide | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Moderate | 1 | [
[
[
1324,
24,
1605
]
],
[
[
1324,
24,
811
],
[
811,
1,
1605
]
],
[
[
1324,
24,
1335
],
[
1335,
40,
1605
]
],
[
[
1324,
24,
126
],
[
126,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Indapamide (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Indapamide (... |
DB01168 | DB01240 | 1,053 | 885 | [
"DDInter1526",
"DDInter657"
] | Procarbazine | Epoprostenol | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
1053,
24,
885
]
],
[
[
1053,
63,
1061
],
[
1061,
1,
885
]
],
[
[
1053,
21,
28936
],
[
28936,
60,
885
]
],
[
[
1053,
63,
1252
],
[
1252... | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Procarbazine (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Epoprostenol (Compound)
Procarbazine may cause a... |
DB00445 | DB08826 | 322 | 1,292 | [
"DDInter655",
"DDInter489"
] | Epirubicin | Deferiprone | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
322,
25,
1292
]
],
[
[
322,
18,
2215
],
[
2215,
57,
1292
]
],
[
[
322,
21,
29124
],
[
29124,
60,
1292
]
],
[
[
322,
24,
45
],
[
45,
... | [
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Epirubicin",
"{u} (Compound) downregulates {v} (Gene)",
"HSPA8"
],
[
"HSPA8",
"{u} (Gene) is downregulated by {v} (Compound)",... | Epirubicin (Compound) downregulates HSPA8 (Gene) and HSPA8 (Gene) is downregulated by Deferiprone (Compound)
Epirubicin (Compound) causes Rash pustular (Side Effect) and Rash pustular (Side Effect) is caused by Deferiprone (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00999 | DB11113 | 504 | 657 | [
"DDInter883",
"DDInter307"
] | Hydrochlorothiazide | Castor oil | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
504,
24,
657
]
],
[
[
504,
1,
1326
],
[
1326,
24,
657
]
],
[
[
504,
63,
891
],
[
891,
24,
657
]
],
[
[
504,
24,
708
],
[
708,
24... | [
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Hydrochlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Diclofenamide"
],
[
"Diclofenamide",
... | Hydrochlorothiazide (Compound) resembles Diclofenamide (Compound) and Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a mod... |
DB00675 | DB01246 | 888 | 820 | [
"DDInter1744",
"DDInter45"
] | Tamoxifen | Alimemazine | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
888,
24,
820
]
],
[
[
888,
1,
358
],
[
358,
24,
820
]
],
[
[
888,
24,
1335
],
[
1335,
24,
820
]
],
[
[
888,
63,
1236
],
[
1236,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Tamoxifen",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may cause a mode... | Tamoxifen (Compound) resembles Orphenadrine (Compound) and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine may cause a moderate interaction t... |
DB00612 | DB01069 | 1,121 | 401 | [
"DDInter216",
"DDInter1533"
] | Bisoprolol | Promethazine | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1121,
24,
401
]
],
[
[
1121,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1121,
24,
104
],
[
104,
24,
401
]
],
[
[
1121,
6,
12523
],
[
12523,
... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdila... |
DB00019 | DB14811 | 1,257 | 385 | [
"DDInter1405",
"DDInter979"
] | Pegfilgrastim | Isatuximab | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic an... | Moderate | 1 | [
[
[
1257,
24,
385
]
],
[
[
1257,
24,
1362
],
[
1362,
24,
385
]
],
[
[
1257,
25,
1064
],
[
1064,
25,
385
]
],
[
[
1257,
24,
1362
],
[
1362,... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isatuximab"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Pegfilgrastim may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead... |
DB08908 | DB09330 | 713 | 985 | [
"DDInter564",
"DDInter1352"
] | Dimethyl fumarate | Osimertinib | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
713,
24,
985
]
],
[
[
713,
63,
168
],
[
168,
23,
985
]
],
[
[
713,
63,
134
],
[
134,
24,
985
]
],
[
[
713,
24,
119
],
[
119,
63,... | [
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
... | Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Vinorelb... |
DB06335 | DB09100 | 761 | 320 | [
"DDInter1646",
"DDInter1799"
] | Saxagliptin | Thyroid, porcine | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyro... | Moderate | 1 | [
[
[
761,
24,
320
]
],
[
[
761,
63,
417
],
[
417,
23,
320
]
],
[
[
761,
63,
1324
],
[
1324,
24,
320
]
],
[
[
761,
24,
1296
],
[
1296,
... | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
... | Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone an... |
DB00705 | DB00912 | 441 | 473 | [
"DDInter496",
"DDInter1581"
] | Delavirdine | Repaglinide | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
441,
24,
473
]
],
[
[
441,
6,
3486
],
[
3486,
45,
473
]
],
[
[
441,
21,
28873
],
[
28873,
60,
473
]
],
[
[
441,
24,
609
],
[
609,
... | [
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Delavirdine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound... | Delavirdine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Repaglinide (Compound)
Delavirdine (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Repaglinide (Compound)
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Clarithr... |
DB05316 | DB12332 | 749 | 1,619 | [
"DDInter1467",
"DDInter1626"
] | Pimavanserin | Rucaparib | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
749,
24,
1619
]
],
[
[
749,
62,
112
],
[
112,
23,
1619
]
],
[
[
749,
24,
1662
],
[
1662,
24,
1619
]
],
[
[
749,
63,
1419
],
[
1419,
... | [
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Pimavanserin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Pimavanserin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric aci... |
DB05154 | DB09280 | 740 | 1,604 | [
"DDInter1517",
"DDInter1101"
] | Pretomanid | Lumacaftor | Persistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern. Research in recent years has been geared toward the development of novel therapies that target persistent forms of this disease, which have shown resistance to standard therapy re... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
740,
25,
1604
]
],
[
[
740,
25,
1017
],
[
1017,
64,
1604
]
],
[
[
740,
63,
372
],
[
372,
24,
927
],
[
927,
64,
1604
]
],
[
[
740,
... | [
[
[
"Pretomanid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Pretomanid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} m... | Pretomanid may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Lumacaftor
Pretomanid may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate in... |
DB01050 | DB05578 | 848 | 330 | [
"DDInter900",
"DDInter1566"
] | Ibuprofen | Ramucirumab | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Major | 2 | [
[
[
848,
25,
330
]
],
[
[
848,
24,
41
],
[
41,
63,
330
]
],
[
[
848,
24,
901
],
[
901,
24,
330
]
],
[
[
848,
63,
1100
],
[
1100,
24,... | [
[
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Levomi... | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran ... |
DB00532 | DB12130 | 208 | 1,017 | [
"DDInter1152",
"DDInter1094"
] | Mephenytoin | Lorlatinib | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
208,
24,
1017
]
],
[
[
208,
62,
608
],
[
608,
23,
1017
]
],
[
[
208,
24,
175
],
[
175,
24,
1017
]
],
[
[
208,
63,
134
],
[
134,
... | [
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mephenytoin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
... | Mephenytoin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamci... |
DB00683 | DB09280 | 1,382 | 1,604 | [
"DDInter1212",
"DDInter1101"
] | Midazolam | Lumacaftor | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
1382,
25,
1604
]
],
[
[
1382,
24,
593
],
[
593,
24,
1604
]
],
[
[
1382,
62,
1573
],
[
1573,
24,
1604
]
],
[
[
1382,
1,
902
],
[
902,
... | [
[
[
"Midazolam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
... | Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Midazolam may cause a minor interaction that can limit clinical effects when taken with Prednisone and Prednisone m... |
DB00696 | DB05812 | 826 | 1,374 | [
"DDInter665",
"DDInter8"
] | Ergotamine | Abiraterone | A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
826,
24,
1374
]
],
[
[
826,
6,
8374
],
[
8374,
45,
1374
]
],
[
[
826,
21,
28996
],
[
28996,
60,
1374
]
],
[
[
826,
25,
760
],
[
760,
... | [
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Ergotamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Ergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Abiraterone (Compound)
Ergotamine (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Abiraterone (Compound)
Ergotamine may lead to a major life threatening interaction when taken wit... |
DB00865 | DB09472 | 939 | 1,383 | [
"DDInter187",
"DDInter1693"
] | Benzphetamine | Sodium sulfate | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
939,
24,
1383
]
],
[
[
939,
1,
1405
],
[
1405,
24,
1383
]
],
[
[
939,
40,
371
],
[
371,
24,
1383
]
],
[
[
939,
64,
1466
],
[
1466,
... | [
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Benzphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u}... | Benzphetamine (Compound) resembles Cyclobenzaprine (Compound) and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Benzphetamine (Compound) resembles Propafenone (Compound) and Propafenone may cause a moderate interaction that could exacerbate diseases when ... |
DB00308 | DB01259 | 347 | 392 | [
"DDInter901",
"DDInter1024"
] | Ibutilide | Lapatinib | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Major | 2 | [
[
[
347,
25,
392
]
],
[
[
347,
21,
28762
],
[
28762,
60,
392
]
],
[
[
347,
23,
112
],
[
112,
23,
392
]
],
[
[
347,
25,
918
],
[
918,
... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
]
],
[
[
"Ibutilide",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)... | Ibutilide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Lapatinib (Compound)
Ibutilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lapatinib
... |
DB00081 | DB06228 | 273 | 792 | [
"DDInter1838",
"DDInter1609"
] | Tositumomab | Rivaroxaban | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Major | 2 | [
[
[
273,
25,
792
]
],
[
[
273,
23,
944
],
[
944,
62,
792
]
],
[
[
273,
24,
1683
],
[
1683,
24,
792
]
],
[
[
273,
63,
1184
],
[
1184,
... | [
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Tositumomab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile"... | Tositumomab may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Rivaroxaban
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinu... |
DB00307 | DB01261 | 1,101 | 170 | [
"DDInter202",
"DDInter1679"
] | Bexarotene | Sitagliptin | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Major | 2 | [
[
[
1101,
25,
170
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
170
]
],
[
[
1101,
21,
28850
],
[
28850,
60,
170
]
],
[
[
1101,
25,
52
],
[
52,
... | [
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sitagliptin"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sitagl... | Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sitagliptin (Compound)
Bexarotene (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Sitagliptin (Compound)
Bexarotene may lead to a major life threatening interaction when taken with Dulaglutide and Dulaglutide may ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.